Biosimilars

EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.

How do you design, refine, and optimize novel GLP-1 drugs that could improve patient experiences? With a computer, of course.

A look at how biosimilars can increase patient access to essential medicines, as well as improve performance in healthcare systems.

Biosimilars, Switzerland and more; we interview Anne Marie de Jonge-Schuermans from the Swiss Biotech Association.

Humira biosimilars finally launch on the US market

Need a refresher on biosimilars? Here, we offer some key points to keep in mind when it comes to structure, function, and interchangeability.

The first Humira biosimilar in the US is here, but market penetration could be a challenge.

Our free eBook showcases content on bioprocess scale up, biosimilars, primary packaging considerations, and more.

How can companies make their mark as the biosimilar market continues to grow?

Biosimilars have been available in Europe for years. Is the US still lagging behind?